Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sumitomo Dainippon Settles Latuda Patent Lawsuits in US, New 5-Year Biz Plan Due Out Next Spring
Sumitomo Dainippon Pharma said on November 27 that it has reached a settlement with all 16 generic firms over patent infringement lawsuits in the US regarding its antipsychotic agent Latuda (lurasidone). Sumitomo Dainippon filed lawsuits jointly with its US unit…
To read the full story
Related Article
- Latuda Challenged Again over Use Patent Validity in US: Sumitomo Dainippon
June 23, 2020
- US Latuda Sales Might Fall Short as Lawsuits Weigh: Sumitomo Dainippon Chief
February 12, 2019
- Sumitomo Dainippon Corrects Announcement on US Latuda Settlement
January 7, 2019
- Latuda Use Patent Suit Could Wrap Up in December: Sumitomo Dainippon Chief
May 14, 2018
- Sumitomo Dainippon Sues 2 Gx Makers over Latuda, Delays New 5-Year-Plan Announcement
February 15, 2018
BUSINESS
- Lenvima-Keytruda Triplets Fail in First-Line RCC Trial
April 22, 2026
- Another Global PIII Shuttered for Arcus-Partnered TIGIT Combo: Taiho
April 22, 2026
- Imdelltra Likely to Gain Ground in 2nd-Line SCLC after Label Update: Oncologist
April 22, 2026
- Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan
April 22, 2026
- Padcev-Keytruda Gets FDA Priority Review for Cisplatin-Eligible Perioperative MIBC
April 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…